Ovarian cancer (OC) is the fifth leading cause of cancer death in women. High mortality rates are due to vague symptoms of early disease, leading to diagnosis at a late stage. Approximately 10% of OCs are considered hereditary. The KRAS-variant is an inherited, germline variant that has been demonstrated to serve as a genetic marker of increased risk of OC. The KRAS-variant is easily tested in a blood or saliva sample, and has been shown to be at a high prevalence in OC patients. This test could serve as an answer to patients with a family history of ovarian and breast cancer without a previously identifiable genetic mutation.
Keywords: Hereditary non-polyposis colorectal cancer; KRAS-variant; MicroRNA; Oncomirs; Ovarian cancer.